stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Operating cash flow
Spyre Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$169.3M, compared with −$157.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$249.3M. Over the past ten years it has ranged from −$169.3M (fiscal 2025) to −$11.0M (fiscal 2015) — the current reading is the lowest in ten years. Operating cash flow has fallen for 4 consecutive fiscal years. Spyre Therapeutics, Inc. ranks 562nd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$169.3M | — |
| FY2024 | −$157.4M | — |
| FY2023 | −$99.9M | — |
| FY2022 | −$80.1M | — |
| FY2021 | −$53.7M | — |
| FY2020 | −$75.8M | — |
| FY2019 | −$65.7M | — |
| FY2018 | −$32.2M | — |
| FY2017 | −$24.6M | — |
| FY2016 | −$18.8M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$77.5M | — |
| Jun 2026 | −$69.9M | — |
| Mar 2026 | −$57.4M | — |
| Dec 2025 | −$44.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $323.9M |
| PTGX Protagonist Therapeutics, Inc. compare | $131.2M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.9M |
| TWST Twist Bioscience Corporation compare | −$53.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$157.0M |
| SYRE Spyre Therapeutics, Inc. | −$249.3M |
| IBRX ImmunityBio, Inc. compare | −$281.1M |
| CYTK Cytokinetics, Incorporated compare | −$572.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement